Signals of multiparty entanglement and holography
Journal of High Energy Physics · 06.06.2025 · 2025 (6)
DOI: 10.1007/jhep06(2025)068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of High Energy Physics, online erschienen am 06.06.2025. Verfasst von Vijay Balasubramanian und 3 weiteren Autor:innen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A bstract We study multiparty entanglement signals, which are functions of a quantum state that are non-zero only when the state has multiparty entanglement. We consider known signals of three- and four-party entanglement, and propose new signals for four- and higher-party entanglement. We make some remarks on their general properties, but mainly focus on using holographic states in AdS 3 /CFT 2 as a test case to explore their properties. For both the AdS vacuum and multiboundary wormhole states, we find that the multiparty entanglement signals are generically non-zero and of order one in units of the central charge of the dual CFT, revealing substantial multiparty entanglement. In the large-horizon limit of multiboundary wormhole states, however, the signals for three or more parties become small, indicating the short-range nature of entanglement.
Zitieren
APA
Balasubramanian, V., Kang, M. J., Murdia, C., & Ross, S. F. (2025). Signals of multiparty entanglement and holography. Journal of High Energy Physics, 2025(6). https://doi.org/10.1007/jhep06(2025)068
Vancouver
Balasubramanian V, Kang MJ, Murdia C, Ross SF. Signals of multiparty entanglement and holography. Journal of High Energy Physics. 2025;2025(6). doi:10.1007/jhep06(2025)068
BibTeX
@article{Balasubramanian2025,
author = {Balasubramanian, Vijay and Kang, Monica Jinwoo and Murdia, Chitraang and Ross, Simon F.},
title = {Signals of multiparty entanglement and holography},
journal = {Journal of High Energy Physics},
year = {2025},
volume = {2025},
number = {6},
doi = {10.1007/jhep06(2025)068}
}
EUVIMED